Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

The Hematology Journal : the Official Journal of the European Haematology Association
I N MicallefT A Lister

Abstract

High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres. Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 microg/kg/day). The harvest was considered successful if > or =1 x 10(6) CD34(+) cells/kg were collected by leukapheresis. The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients). The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years). The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination. At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in > or =2nd remis...Continue Reading

Citations

May 14, 2009·Therapeutics and Clinical Risk Management·Francesca RicciMarco Montillo
Apr 24, 2004·Transfusion·Michael KoenigsmannAstrid Franke
Jan 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigDebra A Welker
Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Sep 12, 2016·Journal of Clinical Apheresis·Gwendolyn van GorkomHarry C Schouten
Mar 23, 2004·Bone Marrow Transplantation·T KuittinenE Jantunen
Oct 6, 2006·Expert Review of Anticancer Therapy·Marco MontilloAlessandra Tedeschi
Oct 28, 2017·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Rajiv KumarVelu Nair
Oct 17, 2008·Expert Opinion on Investigational Drugs·Simon P Fricker
Aug 13, 2011·Internal Medicine Journal·K E HerbertL B To
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matt KalaycioBrian Bolwell
Aug 13, 2011·Blood·L Bik ToKirsten E Herbert
Nov 15, 2018·Journal of Clinical Apheresis·Abdel-Ghani M AzzouqaAbba C Zubair
Jan 11, 2005·British Journal of Haematology·S Paneesha, D W Milligan
Aug 27, 2010·European Journal of Haematology·Esa Jantunen, Gunnar Kvalheim

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.